Key result
Recent approvals of trabectedin and eribulin, along with ongoing trials of targeted agents, are expanding systemic therapy options for metastatic or unresectable well-differentiated and dedifferentiated liposarcoma.
Population
Patients with metastatic or unresectable well-differentiated (WDLS) and dedifferentiated liposarcoma (DDLS)
Design
Review
Authors
Loading...
May support targeted therapy trials in molecularly defined liposarcoma subtypes; leaves open prospective validation before practice change.
This review outlines the current standard of care and emerging systemic therapies for metastatic or unresectable well-differentiated and dedifferentiated liposarcoma.
McGovern et al. (2017) conducted a review in Metastatic or Unresectable Well-Differentiated/Dedifferentiated Liposarcoma. Systemic Therapy was evaluated. Recent approvals of trabectedin and eribulin, along with ongoing trials of targeted agents, are expanding systemic therapy options for metastatic or unresectable well-differentiated and dedifferentiated liposarcoma.
Synapse has enriched 3 closely related papers on similar clinical questions. Consider them for comparative context: